Pluangnooch Panwadee, Timalsena Sunita, Wongkajornsilp Adisak, Soontrapa Kitipong
Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
PLoS One. 2017 Oct 26;12(10):e0186971. doi: 10.1371/journal.pone.0186971. eCollection 2017.
The effectiveness of cytokine-induced killer (CIK) cells for treatment of cancers has long been appreciated. Here, we report for the first time that CIK cells can be applied to treat allergic airway inflammation. Adopting from an established protocol with some modifications, we generated CIK cells ex vivo from mouse T cells, and examined their effectiveness in treatment of allergic airway inflammation using the ovalbumin-induced model of allergic airway inflammation. Based upon evaluation of bronchoalveolar lavage cellularity, T helper type2 cytokine levels and lung histology, all of which are important parameters for determining the severity of allergic airway inflammation, diseased mice treated with CIK cells showed significant reductions in all the parameters without any obvious adverse effects. Interestingly, the observed effects were comparable to those treated with dexamethasone. Thus, our study provides a novel application of CIK cells in treatment of allergic airway inflammation.
细胞因子诱导的杀伤（CIK）细胞治疗癌症的有效性早已得到认可。在此，我们首次报道CIK细胞可用于治疗过敏性气道炎症。我们在对既定方案进行一些修改后，从小鼠T细胞体外生成CIK细胞，并使用卵清蛋白诱导的过敏性气道炎症模型研究其治疗过敏性气道炎症的有效性。基于对支气管肺泡灌洗细胞数量、2型辅助性T细胞细胞因子水平和肺组织学的评估（所有这些都是确定过敏性气道炎症严重程度的重要参数），接受CIK细胞治疗的患病小鼠在所有参数上均有显著降低，且无任何明显不良反应。有趣的是，观察到的效果与地塞米松治疗的效果相当。因此，我们的研究为CIK细胞在治疗过敏性气道炎症方面提供了一种新的应用。
